A Phase 3 interventional study of Esomeprazole and Cimetidine in Stress Ulcer Prophylaxis, sponsored by AstraZeneca. Completed at 16 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-10.
Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Gastrointestinal Hemorrhage with a site in China — 8 open to participants now, 9 under way, 1 of them phase 3. Gastrointestinal Hemorrhage · China.
Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, this one is the 6th largest by enrollment of the 33 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 3, and was the 11th registered.
338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.
Browse Gastrointestinal Hemorrhage studies →8 of the 40 studies in Gastrointestinal Hemorrhage with a site in China are open now. Recruiting first, the newest first:
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–75
Sixth Affiliated Hospital, Sun Yat-sen University · Sites in China
Ages 18–75
Chinese University of Hong Kong · Sites in China
Ages 18+
Xingshun Qi · Sites in China, United States, Brazil and 5 more countries
Ages 18+
Chinese University of Hong Kong · Sites in China, Hong Kong, Thailand
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 49 Gastrointestinal Hemorrhage studies recruiting now, 39 (80%) set no upper age limit and 4 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 5 · Phase 4 5
First in 2004; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 343 is above the median of 98 across 210 interventional studies indexed under Gastrointestinal Hemorrhage.
Median enrollment 101 across the 33 interventional studies, 476 across the 7 observational. Of the 21 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Gastrointestinal Hemorrhage — fewer than ten, so there is no comparison to draw.
2 of the studies in Gastrointestinal Hemorrhage with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129031Phase 3Xijing HospitalOptimization Strategies for Blood Transfusion Protocols in the Emergency Treatment of Hemorrhagic Shock | 2027-06-30 |
| NCT06776029Sixth Affiliated Hospital, Sun Yat-sen UniversityFecal Microbiota Transplantation for Radiation-Induced Proctopathy | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 40 studies in Gastrointestinal Hemorrhage with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The efficacy of esomeprazole will be compared versus cimetidine (a drug that previously demonstrated prevention of bleeding events) during treatment period in proportion of patients for the prevention of upper GI bleeding.
Stress related upper Gastrointestinal (GI) bleedings are important events associated with morbidity and mortality among seriously ill patients. Data from the literature suggest that stress ulcer prevention with effective acid suppressive treatment can reduce bleeding events and is thus an important therapy in high-risk patients. Esomeprazole has the potential to reduce gastric acidity for prolonged periods of time adequate for both preventing mucosal damage and facilitating coagulation. This study is to reveal whether intravenous (iv) esomeprazole is effective in preventing upper gastrointestinal bleeding and if it is tolerated by Chinese seriously ill patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
iv esomeprazole 30 min intermittent infusions given for maximum 14 days
Drug: Esomeprazole
iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
Drug: Cimetidine
iv esomeprazole 30 min intermittent infusions given for maximum 14 days
Also known as: Nexium
iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
Also known as: Tagamet
The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase
Criteria for a clinically significant upper GI bleeding as: 1. Bright red blood per NG or OG tube that did not clear after NG or OG tube adjustment and 5 to 10 minutes of at least 100 ml lavage with room temperature normal saline-or, 2. Persistent gastroccult- positive coffee ground material During IMP treatment Day 1-2: Persistent gastroccult- positive coffee ground material for at least eight consecutive hours that did not clear with at least 100 ml of lavage with room temperature normal saline. During IMP treatment Day 3-14: Persistent gastroccult- positive coffee ground material in at least three consecutive gastric aspirates within 2 to 4 hours (at least 60 ±20 minutes apart), that did not clear with at least 100 ml of lavage with room temperature normal saline.
Time frame: 1-14 days
Proportion of Patients With Any Overt Upper-GI Bleeding (Significant and Non-significant) During the Treatment Evaluation Phase
Criteria for a significant upper GI bleeding as described in primary outcome measure or, Criteria for a non-significant upper GI bleeding as: 1. Bright red blood per NG or OG tube that clear after NG or OG tube adjustment and 5 to 10 minutes of lavage with room temperature normal saline or, 2. Persistent gastroccult- positive coffee ground material During IMP treatment Day 1-2: Persistent gastroccult - positive coffee ground material for at less than eight consecutive hours or that clear with at least 100 ml of lavage with room temperature normal saline. During IMP treatment Day 3-14: Persistent gastroccult - positive coffee ground material in less than three consecutive gastric aspirates within 2 to 4 hours (at least 60±20 minutes apart), or that clear with at least 100 ml of lavage with room temperature normal saline or, 3. Any clinical signs of hematemesis or melena or haematochezia judged (by the Investigator) to be from an upper GI source.
Time frame: 1-14 days
Overall, 343 patients were enrolled from 27 centres in China. The first patient entered the study on 15 July 2014 and the last patient completed the study on 18 February 2016. Of the 343 patients enrolled into the study, 311 (90.7%) patients were randomised to treatment.
| Milestone | Esomeprazole | Cimetidine |
|---|---|---|
| Started | 155 | 156 |
| Completed | 133 | 138 |
| Not completed | 22 | 18 |
| Withdrew: Death | 10 | 4 |
| Withdrew: Eligibility criteria not fulfilled | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 8 |
| Withdrew: Not treated | 8 | 3 |
| Withdrew: Investigator's misjudgement | 1 | 2 |
Criteria for a clinically significant upper GI bleeding as: 1. Bright red blood per NG or OG tube that did not clear after NG or OG tube adjustment and 5 to 10 minutes of at least 100 ml lavage with room temperature normal saline-or, 2. Persistent gastroccult- positive coffee ground material During IMP treatment Day 1-2: Persistent gastroccult- positive coffee ground material for at least eight consecutive hours that did not clear with at least 100 ml of lavage with room temperature normal saline. During IMP treatment Day 3-14: Persistent gastroccult- positive coffee ground material in at least three consecutive gastric aspirates within 2 to 4 hours (at least 60 ±20 minutes apart), that did not clear with at least 100 ml of lavage with room temperature normal saline.
| % of participants | Esomeprazole | Cimetidine |
|---|---|---|
| The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase | 2.7 | 4.6 |
Criteria for a significant upper GI bleeding as described in primary outcome measure or, Criteria for a non-significant upper GI bleeding as: 1. Bright red blood per NG or OG tube that clear after NG or OG tube adjustment and 5 to 10 minutes of lavage with room temperature normal saline or, 2. Persistent gastroccult- positive coffee ground material During IMP treatment Day 1-2: Persistent gastroccult - positive coffee ground material for at less than eight consecutive hours or that clear with at least 100 ml of lavage with room temperature normal saline. During IMP treatment Day 3-14: Persistent gastroccult - positive coffee ground material in less than three consecutive gastric aspirates within 2 to 4 hours (at least 60±20 minutes apart), or that clear with at least 100 ml of lavage with room temperature normal saline or, 3. Any clinical signs of hematemesis or melena or haematochezia judged (by the Investigator) to be from an upper GI source.
| proportion of participants | Esomeprazole | Cimetidine |
|---|---|---|
| Proportion of Patients With Any Overt Upper-GI Bleeding (Significant and Non-significant) During the Treatment Evaluation Phase | 0.109 | 0.105 |
Collected over AEs will be collected from the time of the first administration of IMP until the end of follow-up, up to 15 days. SAEs will be collected from signed inform consent until the end of follow-up, up to 15 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cimetidine | — | 12/153 (7.8%) | 88/153 (57.5%) |
| Esomeprazole | — | 14/147 (9.5%) | 85/147 (57.8%) |
| Event | Cimetidine | Esomeprazole |
|---|---|---|
| Septic shockInfections and infestations | 2/153 | 3/147 |
| Multi-organ failureGeneral disorders | 0/153 | 2/147 |
| Cerebral haemorrhageNervous system disorders | 1/153 | 2/147 |
| Cardio-respiratory arrestCardiac disorders | 0/153 | 1/147 |
| Cardiogenic shockCardiac disorders | 0/153 | 1/147 |
| Low cardiac output syndromeCardiac disorders | 0/153 | 1/147 |
| HypernatraemiaMetabolism and nutrition disorders | 0/153 | 1/147 |
| Systemic sclerosisMusculoskeletal and connective tissue disorders | 0/153 | 1/147 |
| Bronchial haemorrhageRespiratory, thoracic and mediastinal disorders | 0/153 | 1/147 |
| HypercapniaRespiratory, thoracic and mediastinal disorders | 0/153 | 1/147 |
| Event | Cimetidine | Esomeprazole |
|---|---|---|
| Lung infectionInfections and infestations | 31/153 | 28/147 |
| PyrexiaGeneral disorders | 25/153 | 27/147 |
| HypokalaemiaMetabolism and nutrition disorders | 19/153 | 25/147 |
| AnaemiaBlood and lymphatic system disorders | 15/153 | 13/147 |
| ConstipationGastrointestinal disorders | 14/153 | 8/147 |
| HyperglycaemiaMetabolism and nutrition disorders | 9/153 | 13/147 |
| HypoproteinaemiaMetabolism and nutrition disorders | 9/153 | 11/147 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 10/153 | 6/147 |
| Hepatic function abnormalHepatobiliary disorders | 10/153 | 9/147 |
| HypernatraemiaMetabolism and nutrition disorders | 7/153 | 9/147 |
Among 311 randomised patients, 300 patients received randomised treatment: 147 patients in the esomeprazole treatment group and 153 patients in the cimetidine treatment group.
| Age, Continuous(years) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Mean | 50.6 ± 11.8 | 50.1 ± 12.4 | 50.4 ± 12.1 |
| Age, Customized(participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| <65 years | 131 | 132 | 263 |
| >=65 years | 16 | 21 | 37 |
| Sex: Female, Male(Participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Female | 43 | 38 | 81 |
| Male | 104 | 115 | 219 |
| Race/Ethnicity, Customized(participants) | Esomeprazole | Cimetidine | Total |
|---|---|---|---|
| Asian/Chinese | 147 | 153 | 300 |
The record gives a start of Jul 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole